Special Optics offers objective lens solutions optimized for use in two-photon microscopy systems. These apochromatic objectives are customized with high numerical apertures and long working distances for use with various sample sizes and applications.
Lumora Ltd and 3M have signed a joint development and licensing agreement. Conclusion The agreement allows 3M to develop and sell nucleic acid test kits utilising Lumora’s BART technology.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Critical Outcome Technologies Inc. announced recent experiments demonstrating clear evidence of COTI-2's ability to significantly inhibit the growth of cancer cells that over express Akt/Akt2, confirming it as a promising targeted therapy candidate.
Daiichi Sankyo Company submitted a supplemental New Drug Application for an additional indication of Diagnogreen 25 mg intravenous injection for near-infrared fluorescence angiography during cerebrovascular surgery.
Canadian drugmaker Valeant Pharmaceuticals International Inc. said it will buy cold remedy maker Afexa Life Sciences Inc. for about $77.6 million.
A Caris & Co. analyst upgraded the stock of drug developer Alkermes Inc., pointing to the company's pending acquisition of a drug technology business.
A new lupus treatment developed by Human Genome Sciences Inc. is receiving a lukewarm reception from doctors so far, with demand for the drug shaping up to be much softer than expected, according to a Citi analyst.
The National Institutes of Health, in partnership with the Department of Defense, is building a central database on traumatic brain injuries.
Kuros Biosurgery completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.
Ipsen and Inspiration Biopharmaceuticals Inc. entered into a strategic partnership agreement, to create a European hemophilia commercial organization, to launch Inspiration’s hemophilia product portfolio in Europe.
The most common breast cancer uses the most efficient, powerful food delivery system known in human cells and blocking that system kills it, researchers report.
Collaborating researchers at Stanford University and The Scripps Research Institute have identified chemical compounds that show promise as potential therapeutics for a set of medical conditions caused by the abnormal clumping together of a protein known as transthyretin (TTR).
Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer -- mesothelioma, and melanoma of the eye.